CN116942721B - Nasal cavity nursing liquid based on garlicin - Google Patents
Nasal cavity nursing liquid based on garlicin Download PDFInfo
- Publication number
- CN116942721B CN116942721B CN202310595801.6A CN202310595801A CN116942721B CN 116942721 B CN116942721 B CN 116942721B CN 202310595801 A CN202310595801 A CN 202310595801A CN 116942721 B CN116942721 B CN 116942721B
- Authority
- CN
- China
- Prior art keywords
- allicin
- care solution
- nasal
- solution according
- nasal cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003928 nasal cavity Anatomy 0.000 title claims abstract description 31
- 230000000474 nursing effect Effects 0.000 title abstract description 14
- 239000007788 liquid Substances 0.000 title abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims description 25
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims description 25
- 235000010081 allicin Nutrition 0.000 claims description 25
- 241000258920 Chilopoda Species 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- 239000002826 coolant Substances 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 8
- 239000002562 thickening agent Substances 0.000 claims description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 7
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 7
- 235000010413 sodium alginate Nutrition 0.000 claims description 7
- 239000000661 sodium alginate Substances 0.000 claims description 7
- 229940005550 sodium alginate Drugs 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 235000010493 xanthan gum Nutrition 0.000 claims description 7
- 239000000230 xanthan gum Substances 0.000 claims description 7
- 229920001285 xanthan gum Polymers 0.000 claims description 7
- 229940082509 xanthan gum Drugs 0.000 claims description 7
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- 241000209020 Cornus Species 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- 229940041616 menthol Drugs 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 241000759833 Cornus officinalis Species 0.000 claims description 4
- 239000006184 cosolvent Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 2
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 claims description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 claims description 2
- 241001558929 Sclerotium <basidiomycota> Species 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 claims description 2
- 239000000305 astragalus gummifer gum Substances 0.000 claims description 2
- 229940116229 borneol Drugs 0.000 claims description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000294 eucalyptus globulus labille leaf/twig oil Substances 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 229930007503 menthone Natural products 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 241000894006 Bacteria Species 0.000 abstract description 5
- 206010017553 Furuncle Diseases 0.000 abstract description 5
- 206010028781 Nasal vestibulitis Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 210000003695 paranasal sinus Anatomy 0.000 abstract description 3
- 206010028741 Nasal inflammation Diseases 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010039101 Rhinorrhoea Diseases 0.000 description 6
- 235000005979 Citrus limon Nutrition 0.000 description 5
- 244000131522 Citrus pyriformis Species 0.000 description 5
- 206010028748 Nasal obstruction Diseases 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 4
- 208000036071 Rhinorrhea Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 210000002850 nasal mucosa Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000989913 Gunnera petaloidea Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010028740 Nasal dryness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Abstract
The invention relates to the field of nasal cavity nursing, in particular to a garlicin-based nasal cavity nursing liquid, which comprises an active composition, wherein the active composition comprises the following components: the nasal cavity nursing liquid has antibacterial activity to various bacteria, has good treatment effect to nasal furuncles, nasal vestibulitis or inflammation of nasal cavities and sinuses, and has no side effect to tested patients.
Description
Technical Field
The invention relates to the field of nasal cavity nursing, in particular to a nasal cavity nursing liquid based on allicin.
Background
Rhinitis, i.e. inflammatory diseases of the nasal cavity, is an inflammation of the nasal mucosa caused by viruses, bacteria, allergens, various physicochemical factors and certain systemic diseases. Patients with rhinitis can have long-term intermittent or alternative nasal obstruction, which causes dizziness, severe influence on sleeping, work and study, and can also produce mucopurulent nasal discharge which often flows into pharyngeal cavity, and cough and excessive phlegm appear.
Currently Western medicine treatment mainly comprises allergen prevention, drug treatment and the like. However, some allergens, such as dust mites, cannot be completely prevented from contacting, and symptomatic treatment can be performed only by drugs, including nasal hormones, nasal antihistamines, oral antihistamines, leukotriene receptor antagonists and the like, but these drugs have limited therapeutic effects on rhinitis and have certain side effects, such as epistaxis, nasal dryness, dizziness, somnolence, dry mouth and the like.
Disclosure of Invention
The invention aims to: aiming at the technical problems, the invention provides a nasal cavity care solution based on allicin.
The technical scheme adopted is as follows:
An allicin-based nasal care solution comprising an active composition comprising:
Allicin, cornus officinalis fruit extract and centipede extract.
Further, the active composition accounts for 0.5-2.5% of the weight of the nasal cavity care solution.
Further, the weight ratio of allicin, dogwood fruit extract and centipede extract is 0.01-0.05:0.5-1:0.1-1.
Further, the weight ratio of allicin, dogwood fruit extract and centipede extract is 0.01:1:0.5.
Further, the method also comprises a solvent and a cosolvent;
among them, in view of economic cost and use experience, the solvent is preferably water, and in order to improve the solubility of the active composition and the auxiliary agent in water, a cosolvent is also required, and through the test of the inventor, the cosolvent is preferably ethanol and hydrogenated castor oil.
And any one or more of humectant, thickener, cooling agent, flavoring agent.
Further, the humectant is any one or a combination of more of silanized glass acid ester, hyaluronic acid, propylene glycol, glycerol, xylitol, butanediol and propylene glycol.
Further, the thickener is any one or more of sodium alginate, pectin, guar gum, hydroxypropyl guar gum, tragacanth gum, carageenan, xanthan gum and sclerotium gum.
Further, the cooling agent is any one or more of menthol, borneol, eucalyptus globulus oil, menthyl lactate and menthone glycerol ketal.
Further, the weight ratio of the humectant to the thickener to the cooling agent to the flavoring agent is 3-5:0.1-0.5:0.5-1:0.01-0.05.
The invention also provides a preparation method of the garlicin-based nasal cavity care solution, which comprises the following steps:
Adding the active composition into the solvent, heating to 40-60 ℃, stirring for 10-60min, filtering to remove insoluble substances to obtain filtrate, cooling to room temperature, adding one or more of humectant, thickener, cooling agent and flavoring agent, stirring for 1-3h, sterilizing, and packaging.
The invention has the beneficial effects that:
The invention provides a nasal cavity nursing liquid based on garlicin, wherein the garlicin has various medical and health care effects, has different degrees of inhibition or killing effects on pathogenic microorganisms such as various bacteria, viruses and fungi and tumors, has a certain anti-inflammatory effect, can relieve symptoms such as nasal obstruction and nasal discharge caused by rhinitis, contains various glycosides, tannins, vitamins, organic acids, saccharides and minerals, has the effects of tonifying liver and kidney, astringing and replenishing blood, promoting urination and reducing blood pressure, has antioxidant activity, can effectively inhibit invasion of microorganisms such as bacteria, mold and yeast, is a clinically indispensable traditional Chinese medicinal material, has the main effects of calming wind and relieving spasm, dredging collaterals and relieving pain, and has the effects of counteracting toxic substances and dissipating mass, the nasal cavity nursing liquid prepared by taking garlicin, cornus officinalis fruit extract and centipede extract as active components has antibacterial activity on various bacteria, has good side effects on nasal furuncles, pre-nasal vestibulitis or nasal cavity and nasal cavity inflammation, and has no side effects on patients.
Detailed Description
The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention. The technology not mentioned in the present invention refers to the prior art, and unless otherwise indicated, the following examples and comparative examples are parallel tests, employing the same processing steps and parameters.
Allicin: shandong gold Otto chemical Co., ltd;
fructus Corni extract: xian Changyue Biotech Co., ltd; centipede extract: shanxi Sean Biotech Co., ltd;
glass acid: jiangsu Runfeng synthetic technology Co., ltd;
Sodium alginate: jiangsu Runfeng synthetic technology Co., ltd;
Xanthan gum: guangzhou Hua biosciences, inc.;
menthol: wuhan Lax pharmaceutical chemical Co., ltd;
Lemon essence: shanghai island fragrance and flavor Co., ltd;
ethanol: guangzhou city Hua Xin chemical technology Co., ltd;
hydrogenated castor oil: shaanxi Emperor Yao Biotechnology Inc.;
water: child haha purified water.
Example 1:
A nasal cavity nursing liquid based on garlicin comprises the following components: 0.01 part of allicin
1 Part of dogwood fruit extract
Centipede extract 0.5 parts
4 Parts of hyaluronic acid
Sodium alginate 0.15 part
Xanthan gum 0.2 parts
Menthol 0.5 part
Lemon essence 0.015 parts
Ethanol 2 parts
Hydrogenated castor oil 1 part
100 Parts of water.
The preparation method of the allicin-based nasal cavity care solution comprises the following steps:
Mixing ethanol and water to obtain solvent, adding allicin, corni fructus fruit extract and Scolopendra extract into solvent, heating to 50deg.C, stirring for 40min, filtering to remove insoluble substances to obtain filtrate, naturally cooling the filtrate to room temperature, adding hyaluronic acid, sodium alginate, xanthan gum, mentholum and lemon essence, stirring for 2 hr, microwave sterilizing, and packaging.
Example 2:
a nasal cavity nursing liquid based on garlicin comprises the following components:
0.01 part of allicin
1 Part of dogwood fruit extract
Centipede extract 0.5 parts
5 Parts of hyaluronic acid
Sodium alginate 0.25 part
Xanthan gum 0.25 part
Menthol 1 part
Lemon essence 0.05 part
Ethanol 2 parts
Hydrogenated castor oil 1 part
100 Parts of water.
The preparation method of the allicin-based nasal cavity care solution is the same as that of example 1.
Example 3:
a nasal cavity nursing liquid based on garlicin comprises the following components:
0.01 part of allicin
1 Part of dogwood fruit extract
Centipede extract 0.5 parts
Hyaluronic acid 3 parts
Sodium alginate 0.05 part
Xanthan gum 0.05 part
Menthol 0.5 part
Lemon essence 0.01 part
Ethanol 2 parts
Hydrogenated castor oil 1 part
100 Parts of water.
The preparation method of the allicin-based nasal cavity care solution is the same as that of example 1.
Comparative example 1:
Substantially the same as in example 1, except that no allicin was added.
Comparative example 2:
Substantially the same as in example 1, except that the cornel fruit extract was not added. Comparative example 3:
substantially the same as in example 1, except that the centipede extract was not added.
Performance test:
performance test was performed using the nasal cavity care solutions prepared in examples 1 to 3 and comparative examples 1 to 3 of the present invention as a test sample;
① Cytotoxicity test
Taking nasal mucosa of New Zealand white rabbits, flushing tissues by using PBS solution containing double antibodies (100U/ml penicillin and 100ug/ml streptomycin) and precooled at 4 ℃, carefully separating a film mucous membrane layer from submucosal tissues (the slightly yellow surface is an epithelial layer), cutting the mucous membrane, adding 0-1%I type collagenase for digestion (incubation for 30min at 37 ℃), directly adding equal amount of 0.25% trypsin into the enzyme solution with mucous membrane blocks after digestion, gently blowing for 5min, removing mucous membrane blocks, centrifuging cell suspension (1200 r/min,5 min), discarding supernatant, adding a proper amount of culture medium containing 10% FBS into cell sediment, and inoculating to a cell culture bottle after uniform blowing;
adding DMEM/F12 culture medium containing 10% fetal bovine serum into rabbit nasal mucosa epithelial cells, placing into a 25cm 2 culture flask, and culturing in a culture box containing 5% CO 2 at 37deg.C;
Taking rabbit nasal mucosa epithelial cells in logarithmic growth phase, inoculating into 96-well plates at a density of 1X 10 5/ml, culturing in a culture box at 37 ℃ for 24 hours in 5% CO 2 per well, discarding culture medium in the 96-well plates, adding 100ul of test solution into a test group, wherein a normal group (fresh culture medium is added), a negative control group (physiological saline is added) and a sample group (nasal cavity nursing solution prepared in examples 1-3 and comparative examples 1-3 are respectively added), and culturing for 24 hours continuously in 6 compound holes per group. The liquid in the wells was discarded, 20ul of 5mg/ml MTT solution was added to each well, the culture was continued for 4 hours, the culture broth was aspirated, 100ul of DMSO was added, and the mixture was shaken on a shaker at low speed for 10min. The plates were shaken and the OD at 490nm of each well was measured with an ELISA reader to calculate cell viability.
The test results are shown in table 1 below:
Table 1:
| Cell viability/% | |
| Blank control | 100 |
| Negative control | 106.20±3.5 |
| Example 1 | 106.64±2.68 |
| Example 2 | 107.26±4.76 |
| Example 3 | 108.60±3.52 |
| Comparative example 1 | 104.03±2.31 |
| Comparative example 2 | 107.35±3.92 |
| Comparative example 3 | 111.97±3.03 |
As is clear from Table 1, the nasal cavity care solutions prepared by the present invention all had cell viability rates of > 99%, and were judged to be non-cytotoxic.
② Antibacterial property test
Inoculating each strain (Escherichia coli, staphylococcus aureus and Bacillus subtilis) to LB liquid culture medium, activating for 2 times at 37deg.C/24 h, and under aseptic operation condition, picking a ring of activated thallus Porphyrae with inoculating loop, placing into 100ml sterile physiological saline, shaking thoroughly, and making into bacterial suspension. The concentration of the bacterial suspension is deduced by measuring the optical density value of the bacterial suspension by a turbidimetry method, namely the bacterial suspension is poured into a cuvette, sterile physiological saline is used as a reference, and the OD value of each bacterial suspension is measured at 600nm so as to ensure that the concentration of each bacterial suspension used in each test is consistent;
Taking sterile culture dishes, adding 15-20ml of sterile culture medium into each dish, cooling and solidifying, sucking 0.1ml of bacterial suspension onto the culture medium by using a sterile pipettor, and uniformly coating by using a sterile coater. After air-drying, sterilized oxford cups were placed on a culture medium at equal distance by using sterile forceps, 4 of them were placed on each dish, one dish was added with 0.1ml of sterile physiological saline as a blank control, the other was added with 0.1ml of sample as a parallel, and the culture was performed at 37 ℃/24 hours, and the diameter (mm) of each inhibition zone was measured with a ruler and the data was recorded, and the results are shown in table 2 below.
Table 2:
as shown in the table 2, the nasal cavity care solution cells prepared by the invention have obvious inhibition effects on escherichia coli, staphylococcus aureus and bacillus subtilis, wherein the inhibition effect on escherichia coli is strongest, staphylococcus aureus is inferior and bacillus subtilis is weakest.
③ Treatment scoring investigation
60 Subjects, 30 women, 30 men, aged 12-54 years, and average aged 34 years, had nasal furuncles, nasal vestibulitis, or nasal and sinus inflammation times of 1-3 years. The differences in age, sex, course of disease, symptoms, etc. are statistically significant.
Human selection standard: patients with nasal furuncles, nasal vestibulitis or inflammatory attacks of the nasal cavity and sinuses, manifested as itching nose, runny nose, nasal obstruction.
The using method comprises the following steps: all patients were discontinued for more than 7 days with other therapeutic drugs, and the nasal cavity care solution prepared in example 1 of the present invention was administered to the patients to be tested, using a spray method, 5 sprays at a time, 3 times/d.
The evaluation method comprises the following steps: itching, runny nose, nasal obstruction, respectively scored by the clinician; the index is rated in four classes: level 0: absence (no symptoms); stage 1: mild (nasal itching); 2 stages: moderate (itching and runny nose); 3 stages: severe (itching, runny nose, nasal obstruction).
Nasal symptom assessment was graded before treatment, 15d, 30d, and the number of individuals at each level was counted, as shown in table 3.
Table 3:
as shown in the table 3, the nasal cavity nursing liquid prepared by the invention has good treatment effect on nasal furuncles, nasal vestibulitis or inflammation of nasal cavities and sinuses, and no side effect is produced for tested patients.
The above embodiments are only for illustrating the technical solution of the present invention, and are not limiting; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims (8)
1. An allicin-based nasal care solution, comprising an active composition, wherein the active composition is:
allicin, cornus officinalis fruit extract and centipede extract;
the weight proportion of the active composition in the nasal cavity care solution is 0.5-2.5%;
the weight ratio of allicin, dogwood fruit extract to centipede extract is 0.01-0.05:0.5-1:0.1-1.
2. The allicin-based nasal care solution according to claim 1, wherein the weight ratio of allicin, cornus officinalis fruit extract and centipede extract is 0.01:1:0.5.
3. The allicin-based nasal care solution according to claim 1, further comprising a solvent and a co-solvent;
And any one or more of humectant, thickener, cooling agent, flavoring agent.
4. The allicin-based nasal care solution according to claim 3, wherein the humectant is any one or more of hyaluronic acid, propylene glycol, glycerin, xylitol, butylene glycol, and propylene glycol.
5. The allicin-based nasal care solution according to claim 3, wherein the thickener is any one or more of sodium alginate, pectin, guar gum, tragacanth gum, carrageenan, xanthan gum, sclerotium gum.
6. The allicin-based nasal care solution according to claim 3, wherein the cooling agent is any one or more of menthol, borneol, eucalyptus globulus oil, menthyl lactate, menthone glycerol ketal.
7. The allicin-based nasal care solution according to claim 3, wherein the weight ratio of the humectant, the thickener, the cooling agent and the flavoring agent is 3 to 5:0.1-0.5:0.5-1:0.01-0.05.
8. The method for preparing a garlicin-based nasal care solution according to claim 3, wherein the active composition is added into the solvent, heated to 40-60 ℃, stirred for 10-60min, filtered to obtain a filtrate, cooled to room temperature, and then one or more of the humectant, the thickener, the cooling agent and the flavoring agent are added, stirred for 1-3h, sterilized and packaged.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310595801.6A CN116942721B (en) | 2023-05-25 | Nasal cavity nursing liquid based on garlicin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310595801.6A CN116942721B (en) | 2023-05-25 | Nasal cavity nursing liquid based on garlicin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116942721A CN116942721A (en) | 2023-10-27 |
| CN116942721B true CN116942721B (en) | 2024-06-28 |
Family
ID=
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309840A (en) * | 2016-08-31 | 2017-01-11 | 顾明明 | Chinese and western medicine combined preparation for treating atrophic rhinitis and preparation method |
| CN106361688A (en) * | 2016-08-26 | 2017-02-01 | 朱高 | Nasal lotion as well as preparation method and application thereof |
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106361688A (en) * | 2016-08-26 | 2017-02-01 | 朱高 | Nasal lotion as well as preparation method and application thereof |
| CN106309840A (en) * | 2016-08-31 | 2017-01-11 | 顾明明 | Chinese and western medicine combined preparation for treating atrophic rhinitis and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105561288B (en) | A kind of bioadhesive hydrogel and film containing alanyl glutamine | |
| US10111925B2 (en) | Formulations comprising plant extracts | |
| WO2019109590A1 (en) | Ophthalmic drug preparation and uses thereof | |
| CN108078975A (en) | Application of the pharmaceutical composition containing eucalyptol, limonene and australene in the drug for preparing treatment upper respiratory tract bacterium infection | |
| CN1256954C (en) | Blumea oil dripping pills and its preparation process | |
| CN113332244A (en) | Antiviral oral spray and preparation method thereof | |
| CN112386628A (en) | Elsholtzia volatile oil nanoemulsion and application thereof | |
| WO2019119720A1 (en) | Fudosteine solution preparation for aerosol inhalation, and preparation method therefor | |
| CN104042640A (en) | Nasal spray of seaweed extract and preparation method thereof | |
| CN116942721B (en) | Nasal cavity nursing liquid based on garlicin | |
| CN116942721A (en) | Nasal cavity nursing liquid based on garlicin | |
| CN114848707B (en) | Oral cavity atomized liquid and its use | |
| CN105749260B (en) | Lysozyme hydrochloride vaginal tablet and preparation method and application thereof | |
| CN111905058A (en) | Pharmaceutical composition for skin mucosa nursing and wound repair and preparation method thereof | |
| CN113730361B (en) | Mucous membrane applicable exosome preparation with needleless injection effect and preparation method thereof | |
| CN109820947A (en) | A kind of application of Chinese medicine composition in preparation treatment epithelium healing cough syndrome drug | |
| KR20190057727A (en) | Composition for improving bronchial health improved palatability | |
| CN111743922B (en) | Composition for improving colonization and activity of probiotics in nasal cavity and application of composition in nasal cavity care | |
| EP3708153A1 (en) | Solution preparation for aerosol inhalation of carbocisteine, and preparation method therefor | |
| CN113952498A (en) | Chinese medicine multi-component liquid wound healing dressing and preparation method thereof | |
| CN107823442B (en) | Hemostatic and anti-infectious pharmaceutical composition | |
| CN113018365A (en) | Compound dragon's blood dental ulcer medicine composition and preparation method thereof | |
| CN115518111B (en) | Chinese herbal compound preparation for treating rhinitis and preparation method thereof | |
| CN117224518B (en) | Application of sofalcone in preparation of medicine for preventing/treating allergic asthma | |
| CN104434992A (en) | Biological adhesive vaginal tablet of periplaneta americana extract and preparation method of biological adhesive vaginal tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |